...
首页> 外文期刊>The American Journal of Cardiology >Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions
【24h】

Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions

机译:心力衰竭患者心脏重新同步治疗后环利尿剂量和结果的变化,左心室喷射分数减少

获取原文
获取原文并翻译 | 示例
           

摘要

Cardiac resynchronization therapy (CRT) improves cardiac hemodynamics. Therefore, the maintenance dose of loop diuretic therapy might be reduced. Consecutive patients who underwent CRT (n = 648) were retrospectively evaluated. Loop diuretic dose was recorded at baseline before implantation and 6 months later with patients classified into 4 groups: (1) no loop diuretic, (2) down-titration, (3) unchanged dose, and (4) up-titration. Afterward total loop diuretic exposure was calculated. Renal function trajectories were evaluated as the difference between implantation and censoring serum creatinine (Cr) value. Clinical outcome was evaluated as the combined end point of heart failure readmissions and all cause mortality. Independent predictors of successful loop diuretic down-titration were identified. Two hundred ninety-six patients (46%) received no loop diuretic at follow-up, 126 (19%) underwent down-titration, 137 (21%) remained on a stable dose, and 89 (14%) underwent up-titration. In comparison with the group that was free from loop diuretics (Cr = +0.06 mg/dl), renal function deteriorated faster during follow-up in patients on stable doses (Cr = +0.29 mg/dl; p = 0.045) and those underwent up-titration (Cr = +0.44 mg/dl; p = 0.009) but not in patients who were down-titrated (Cr = +0.13 mg/dl; p = 1.00). Patients receiving down-titration had a lower risk for the combined clinical end point (adjusted hazards ratio 0.43; confidence interval 0.22 to 0.83; p = 0.012). Factors associated with successful down-titration after 6 months of CRT included nonischemic cardiomyopathy, higher baseline dose of diuretics, higher ejection fraction at 6 weeks, and lower right ventricular systolic pressure at 6 weeks. In conclusion, after CRT, down titration of loop diuretics is often feasible and associated with improved outcome and a slower rate of kidney function decline. Patients with nonischemic cardiomyopathy, treated with high doses of loop diuretics before implantation and beneficial left ventricular remodeling with CRT, are most likely to tolerate loop diuretic down-titration. (C) 2017 Elsevier Inc. All rights reserved.
机译:心脏再同步治疗(CRT)改善了心脏血流动力学。因此,可以减少环路利尿疗法的维持剂量。回顾性评估了接受CRT(n = 648)的连续患者。在植入前和6个月之前记录在基线的基线时,与分类为4组的患者:(1)没有回收利尿剂,(2)下滴定,(3)不变剂量,和(4)升高。之后的总环预防利尿暴露是计算的。评估肾功能轨迹作为植入和污染血清肌酐(CR)值之间的差异。临床结果评估为心力衰竭入伍的结合终点,所有原因死亡率。确定了成功回路利尿下滴定的独立预测因子。在随访中不接受两百六所患者(46%),在随访中没有回路利尿剂,126(19%)在稳定剂量上留下126(19%),137(21%),89(14%)接受上滴定。与没有环路利尿的基团(Cr = + 0.06mg / dl)相比,在稳定剂量的患者的随访期间肾功能更快地恶化(Cr = +0.29 mg / dl; p = 0.045)和接受的患者上滴定(Cr = + 0.44mg / dl; p = 0.009),但不在滴定滴定的患者中(Cr = + 0.13mg / dl; p = 1.00)。接受滴滴涕的患者对组合临床终点的风险较低(调节危险比0.43;置信区间0.22至0.83; p = 0.012)。在CRT 6个月后,与成功下滴定相关的因素包括非缺血性心肌病,高等基线剂量的利尿剂,6周内较高的喷射部分,6周右心室收缩压。总之,在CRT之后,滴落利尿剂的滴定通常是可行的并且与改善的结果和较慢的肾功能率下降相关。患有非缺血性心肌病的患者,在植入和有益的左心室重塑之前用高剂量的环路利尿剂治疗,最有可能耐受环利尿下滴定。 (c)2017年Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号